ArticleNuclear medicine and molecular imaging2015
Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report.
Article in Nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment.Journal of neuroendocrinology · 2026Review
- Imaging-derived biomarkers fromCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Unveiling the potential of copper-61 vs. gallium-68 for SSTR PET imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Emerging innovations in theranostics for pancreatic neuroendocrine tumors.NPJ precision oncology · 2025Review
- Structured reporting of neuroendocrine tumors in PET/CT using [Scientific reports · 2025Article
- Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer.Pharmaceutics · 2024Article
- Head-to-head comparison between [European journal of nuclear medicine and molecular imaging · 2024Article
- Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.Theranostics · 2024Review
- Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors.Pharmaceutics · 2023Review
- Evaluation of reconstruction methods and image noise levels concerning visual assessment of simulated liver lesions inEJNMMI physics · 2023Article
- A Systematic Review on Combined [Journal of clinical medicine · 2023Review
- [European journal of nuclear medicine and molecular imaging · 2023Article
- The New Radiolabeled PeptideCancers · 2022Article
- EVALUATION OF THE SPATIAL RESOLUTION IN MONTE CARLO-BASED SPECT/CT RECONSTRUCTION OF 111IN-OCTREOTIDE IMAGES.Radiation protection dosimetry · 2021Article
- Cost-Effectiveness Analysis ofDiagnostics (Basel, Switzerland) · 2021Article
- Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.Frontiers in endocrinology · 2021Review
- [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].Der Radiologe · 2020Review
- Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature.Medicine · 2019Review
- Role of Combined [Journal of clinical medicine · 2019Review
- Synthesis and Evaluation ofContrast media & molecular imaging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn-pentetreotide has been used for neuroendocrine tumors expressing somatostatin receptors. Recently, (68)Ga-DOTATOC PET has been used with the advantage of high image quality. In this study, we compared quantitative indices between (111)In-pentetreotide SPECT/CT and (68)Ga-DOTATOC PET/CT.
methodsThirteen patients diagnosed with neuroendocrine tumors were prospectively recruited. Patients underwent (111)In-pentetreotide scans with SPECT/CT and (68)Ga-DOTATOC PET/CT before treatment. The number and location of lesions were analyzed on both imaging techniques to compare lesion detectability. Additionally, the maximal uptake count of each lesion and mean uptake count of the lungs were measured on both imagings, and target-to-normal lung ratios (TNR) were calculated as quantitative indices.
resultsAmong 13 patients, 10 exhibited lesions with increased uptake on (111)In-pentetreotide SPECT/CT and/or (68)Ga-DOTATOC PET/CT. Scans with SPECT/CT detected 19 lesions, all of which were also detected on PET/CT. Moreover, 16 additional lesions were detected on PET/CT (6 in the liver, 9 in the pancreas and 1 in the spleen). PET/CT exhibited a significantly higher sensitivity than SPECT/CT (100 % vs. 54 %, P < 0.001). TNR was significantly higher on PET/CT than on SPECT/CT (99.9 ± 84.3 vs. 71.1 ± 114.9, P < 0.001) in spite of a significant correlation (r = 0.692, P = 0.01).
conclusionGa-DOTATOC PET/CT has a higher diagnostic sensitivity than (111)In-pentetreotide scans with SPECT/CT. The TNR on PET/CT is higher than that of SPECT/CT, which also suggests the higher sensitivity of PET/CT. (111)In-pentetreotide SPECT/CT should be used carefully if it is used instead of (68)Ga-DOTATOC PET/CT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.